Clinical Trial Update: Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 study of dasatinib in combination with chemotherapy for relapsed or refractory core-binding factor acute myeloid leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Core-binding Factor Acute Myeloid Leukemia

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: Emory University | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: WITHDRAWN